Longevity is an orphan, and aging is not official disease. So we investid in e traditional biattack and medical devices with one very important criteria: they should produce a side effect of significant improvement on life span. And they should also be as affordable and accessible as possible. Out of 16 companies t we invested, four are already public, and we expect three more ipo by the end of the ar owir,. The average holding period a little bit above two years. This was the fastest transformation from private to public i've ever seen in any of my portfolio. It's always going to be a combination of the things like nine hole marks of aging, a or a lot technologies within